Jeena Sikho Lifecare Limited — Investor Meet, 13-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Jeena Sikho Lifecare reported robust Q3 FY26 results: operational income reached INR 221.7 Cr, EBITDA INR 100.8 Cr (45% margin), and PAT INR 66.7 Cr (30% margin), all showing significant YoY growth. Strong Ayurvedic service demand and increased product sales were key drivers. Management is aggressively expanding, launching new OTC products (NutriRoz next) and finalizing a B2B distribution deal with Entero for broader market reach. International expansion is also active in UAE, Kazakhstan, and Nepal. The strategic focus on integrated healthcare, wellness, and education benefits from improved health insurance reimbursements. Management is highly confident in operational excellence, targeting a long-term INR 1000 Cr profit.